VIDEO: Skyrizi induces clinical remission, endoscopic response in Crohn’s
LAS VEGAS – Patients dosed with Skyrizi for Crohn’s disease achieved clinical remission, endoscopic response and persistent improvements to inflammatory biomarkers consistent with a dose-response relationship.
“This was exciting to finally see the 52-week induction study for risankizumab [Skyrizi, AbbVie] for Crohn's disease,” Marla Dubinsky, MD, of the Icahn School of Medicine, said in a Healio Gastroenterology video exclusive. “We hope to look for approval sometime in 2022.”
Collapse
Dubinksy M, et al. Abstract: Efficacy and safety of risankizumab as maintenance therapy in patients with Crohn's disease: 52-week results from the phase 3 FORTIFY study. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021. Las Vegas (hybrid meeting).
Read more about